Gene Therapy R&D and Revenue Forecasts 2016-2026, Visiongain

Visiongain’s released a new 2016 report which gives investors revenue forecasts to 2026 for the world gene therapies market, submarkets and leading products.
According to the press release:

Scope of our analysis – the technologies whose potential you discover
In this report visiongain defines gene therapy as products modifying the expression of particular genes or correcting abnormal genes.
Therefore this study excludes some agents that may be considered as gene therapies under wider definitions, such as gene silencing and oligonucleotide therapies, antisense therapy and immune system stimulators.

Click here to view the full press release.